Plant Health Care (AIM: PHC) offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes, and rice, as well as specialty crops such as fruits and vegetables. The Group operates globally through subsidiaries, distributors and supply agreements with major industry partners. Plant Health Care’s patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.
In a trading update for the 12 months ending 31 December 2022, revenues were up 40% on the prior period to US411.8m, with a cash balance of US$5.7m. Losses improved 24% to US3.5m with the group announcing “The company is on track to deliver cash breakeven, profitability and internally funded growth within existing financial resources.”
Approval for Sale of Harpinαβ Granted in Belgium Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological …
Plant Health Care Announces China Distribution with AMVAC Plant Health Care® (AIM.PHC.L), a leading provider of peptides used by growers …
Mexico approves PHC68949 to Control Nematodes in Vegetable Crops Plant Health Care® (AIM.PHC.L), a leading provider of peptides used by …
Mexico approves SAORI® to Control Diseases in Vegetables, Berries and Grapes Plant Health Care® (AIM.PHC.L), a leading provider of peptides …
Brazil approves TEIKKO™ (PHC68949) to Control Nematodes in Soybeans Plant Health Care® (AIM.PHC.L), a leading provider of peptides used by …
Trading update Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is …
| P&L | 31 Dec 2022 US$~000 | 31 Dec 2021 US$~000 |
|---|---|---|
| Revenue | 11,767 | 8,432 |
| Cost of sales | (4,596) | (3,429) |
| Gross Profit | 7,171 | 5,003 |
| Profit before tax | (9,447) | (6,415) |
| Balance Sheet | 31 Dec 2022 US$~000 | 31 Dec 2021 US$~000 |
|---|---|---|
| Cash | 5,656 | 1,005 |
| Total assets | 13,824 | 18,210 |
| Total liabilities | 4,134 | 3,852 |
| Total net assets | 9,690 | 14,358 |
Directors
Other
UK Investor Magazine
“John-Marc Bunce, analyst at the group’s NOMAD and Broker Cenkos Securities, has re-iterated his Buy rating on its shares, suggesting a 33p Target Price. His estimates for the year to end December 2022 suggest revenues of $11.4m ($8.4m) with the annual loss significantly reduced to a third lower at $3.0m ($4.6m). Looking at his figures for the current year he sees $15.9m sales, leading to just a small loss of $0.3m. However, for 2024 he forecasts a major uplift in the group’s fortunes – $24.8m sales, a $5.2m profit, worth 1.6c per share in earnings.”
Plant Health Care Website
“…regulatory authorities around the world are adopting accelerated regulations, which allow biological products to come to market more quickly than conventional agrochemicals. In addition, biological products tend to cost far less to develop than conventional agrochemicals. The demand for biological products is increasing rapidly as a result.”
